Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

Schultz, Paul; Herr, Harry W.; Zhang, Zuo‐Feng; Bajorin, Dean F.; Seidman, A. D.; Sarkis, A.; Fair, William R.; Scherr, Douglas S.; Bosl, George J.; Scher, Howard I.

doi:10.1200/jco.1994.12.7.1394

Cited by 145 publications

(46 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Tumor stage at diagnosis is an independent predictor of bladder cancer survival. 12,13 Although a stage disparity persists between blacks and other ethnic groups, the gap has narrowed somewhat over the last 30 years. Black patients today are more likely to present with localized disease than their historical counterparts.…”

Section: Commentmentioning

confidence: 99%

Ethnic Differences in Bladder Cancer Survival

Yee¹,

Lowrance²,

Herr³

et al. 2009

Journal of Urology

View full text Add to dashboard Cite

Objectives-Racial disparities in bladder cancer outcomes have been documented with poorer survival observed among blacks. Bladder cancer outcomes in other ethnic minority groups are less well described. We examined trends in bladder cancer survival among whites, blacks, Hispanics, and Asian/Pacific Islanders in the US over a 30-year period. Results-Blacks presented with higher stage disease than whites, Hispanics and Asian/Pacific Islanders, although a trend toward earlier stage presentation was observed in all groups over time. Five-year disease-specific survival was consistently worse for blacks than for other ethnic groups, even when stratified by stage and grade. Five-year disease-specific survival was 82.8% in whites compared with 70.2% in blacks, 80.7% in Hispanics and 81.9% in Asian/Pacific Islanders. There was a persistent disease-specific survival disadvantage in black patients over time which was not seen in the other ethnic groups. Methods-FromConclusions-Ethnic disparities in bladder cancer survival persist between whites and blacks, while survival in other ethnic minority groups appears similar to that of whites. Further study of access to care, quality of care and treatment decision making among black patients is needed to better understand these disparities.

show abstract

Section: Commentmentioning

confidence: 99%

Ethnic Differences in Bladder Cancer Survival

Yee¹,

Lowrance²,

Herr³

et al. 2009

Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Initial tumor stage and clinical response to chemotherapy were found to be independent prognostic factors. In multivariate analysis, attainment of PO status was the only significant prognostic factor for survival (34). These data demonstrate that response to chemotherapy is a prognostic factor of extreme importance, and should be considered when making clinical decisions for our patients.…”

Section: Neo-adjuvant Chemotherapymentioning

confidence: 83%

Bladder Preservation—a Prospect for Patients with Urinary Bladder Cancer

Sternberg¹

1995

Acta Oncologica

View full text Add to dashboard Cite

“…Since there are no tumor markers yet that can beforehand detect responders to NAC, certain clinicopathological factors were suggested to affect the treatment response. The relation between the response rate and stage of the 1 ry tumor was previously proved in a trial done by Schultz et al who reported overall response rates after neoadjuvant MVAC in patients with T3b and T4a tumors to be approximately 81% and 9%, respectively 23 . In the present study the overall response rate in patients with T3 was 88% and in patients with T4 was 57% (p = 0.02).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt

Khateeb

Hameed

Moeen

et al. 2017

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Background: Bladder cancer is a common health problem is Egypt where it is the 3 rd common cancer (6.9%) in both sexes and the 2 nd common (10.7%) among males. Neoadjuvant chemotherapy has proven benefits in treatment of muscle invasive bladder cancer (MIBC), yet it is still underutilized. Aim: To study the response to neoadjuvant chemotherapy in patients with MIBC and their attitude towards definitive treatment after completion of neoadjuvant therapy. Methods: In this prospective study, 85 patients with MIBC were recruited between September 2013 and September 2014. They were scheduled to receive three cycles of gemcitabine (1000 mg/m 2 , on days 1 and 8) plus cisplatin (75 mg/m 2 on day 1) or carboplatin (AUC=5 on day 1) in patients with impaired renal function prior to definitive treatment. Results: Sixty-seven patients were evaluable for response and toxicity. The majority (79%) were males and their median age was 61 years (range: 38-84). The initial T stage was T3 or T4 in 72% of patients. Complete response was documented in 6 (9%) patients, partial response in 41 (61.2%), stationary disease in 5 (7.5%) and progressive disease in 15 (22.4%). Grade III and IV toxicities were infrequent (5%) with no chemotherapy-related mortality. After completion of the treatment, 9 (13.4%) patients were shifted to bladder preservation treatment due to complete radiological response and refusal of surgery. Conclusion: Neoadjuvant chemotherapy is feasible in MIBC patients in our setting as it gives good clinical response. If offered in a proper way, it doesn't preclude the patients' chances for definitive treatment.

show abstract

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

Cited by 145 publications

References 0 publications

Ethnic Differences in Bladder Cancer Survival

Ethnic Differences in Bladder Cancer Survival

Bladder Preservation—a Prospect for Patients with Urinary Bladder Cancer

Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt

Contact Info

Product

Resources

About